IMV Inc. · OTC:IMVIF
IMV — Immunovaccine — Investor Presentation (January 2013)
28 slides from IMV's investor presentation, January 2013
Slide 1: Corporate Presentation
January 2013 CORPORATE PRESENTATION John Trizzino, CEO Immunovaccine Inc. (TSX-V: IMV) Awarded 2012 Best Early Stage Biotechnology Company
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This document contains forward-looking information pursuant to applicable securities law. All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are based on the estimates a
Slide 3: DepoVax: Delivering the right antigen and adjuvant in a depot vaccine
DEPOVAX™ DELIVERING THE RIGHT ANTIGEN AND ADJUVANT IN A DEPOT VACCINE
Slide 4: Advancing Breakthrough Vaccines & the DepoVax Platform
ADVANCING BREAKTHROUGH VACCINES & THE DEPOVAX™ PLATFORM • DepoVax™ a novel adjuvanting technology platform – Fast, strong and long-lasting immune response – Well developed technology with a breadth of internal and external programs • Clinical-stage therapeutic cancer vaccines – DPX-0907 – Successful
Slide 5: Immunovaccine's Pipeline
IMMUNOVACCINE’S PIPELINE DEPOVAX™ PLATFORM Cancer Vaccine Program Research Preclinical Phase I Phase II Phase III DPX-0907 Breast, ovarian and prostate DPX-Survivac Protocol Cleared Multi-cancer vaccine; initially ovarian cancer Infectious Disease Malaria RSV Anthrax Bio-defense Addiction Program Co
Slide 6: DepoVax Key Components Drive Robust Immune Response
DEPOVAX™ KEY COMPONENTS DRIVE ROBUST IMMUNE RESPONSE Encapsulate in a Liposome Antigen + Adjuvant Suspend in Oil • Specific and enhanced • Holds and presents antigen + adjuvant immune response combination to the immune system • Flexible: applicable to various • Strongly attracts immune cells to the
Slide 7: Creating the Ultimate Depot Effect
CREATING THE ULTIMATE “DEPOT” EFFECT DepoVax™ Elicits Powerful Immune Response Immune cells DepoVaxTM-based vaccine Histology of subcutaneous injection site in mouse Efficiently attracting antigen-presenting cells to vaccine site 7 Immunovaccine Proprietary Information
Slide 8: DepoVax Advantages & Applications
DEPOVAX™ ADVANTAGES & APPLICATIONS Overall Advantages Fast, strong and long-lasting immune response Humoral and/or cellular response possible Compatible with different antigens Stable formulation: easy to re-suspend and administer DepoVax™ in Cancer DepoVax™ in Infectious Disease Maintain remi
Slide 9: DepoVax Intellectual Property and Manufacturing in Place
DEPOVAX ™ INTELLECTUAL PROPERTY AND MANUFACTURING IN PLACE • Issued patents provide broad protection – Any antigen, any adjuvant, any indication – Initial patent protection through 2021 – Additional pending patents extend protection to 2028 and 2031 • Scalable GMP manufacturing process established –
Slide 10: Clinical-Stage Therapeutic Cancer Vaccines
CLINICAL-STAGE THERAPEUTIC CANCER VACCINES
Slide 11: Principles for a Successful Anti-Cancer Vaccine
IMMUNOVACCINE’S PRINCIPLES FOR A SUCCESSFUL ANTI-CANCER VACCINE Right Antigen, Right Technology, Right Strategy The Right Antigen(s) • Target tumor cells, not healthy cells The Right Vaccine Technology • DepoVax™ optimizes presentation of vaccine – resulting in enhanced immunogenicity The Right Prod
Slide 12: DPX-Survivac Advances Standard of Care
DPX-SURVIVAC ADVANCES STANDARD OF CARE Treating Cancer as a Chronic Disease • Administered in the maintenance setting following surgery/ radiation/ chemotherapy • DPX-Survivac intended to attack circulating tumor cells • Sustain remissions • Prevent metastases Cancer Surgery DPX-Survivac Monitor for
Slide 13: DPX-Survivac: A Multi-Cancer Vaccine
DPX-SURVIVAC: A MULTI-CANCER VACCINE Delivering Survivin in DepoVax™ Significantly Enhances Immunogenicity • Targets tumor-associated antigen survivin – Broadly expressed in many solid tumors and hematological cancers: ovarian, breast, non small cell lung cancer (NSCLC), melanoma and myeloma – Tumor
Slide 14: DPX-Survivac Positive Phase I Results
DPX-SURVIVAC POSITIVE PHASE I RESULTS Targeted, Dose-Related, Consistent, Robust and Safe Immune Responses • Targeted Immune Response – Produced in all patients following only one or two vaccinations with Survivac in combination with cyclophosphamide • Suggested Dose-Related Activity – Higher DPX-Su
Slide 15: Robust Antigen Specific Immune Response in Ovarian Cancer Patients
ROBUST ANTIGEN SPECIFIC IMMUNE RESPONSE IN OVARIAN CANCER PATIENTS Dose-Related Immune Response Activity n=6 n=3 1000 n=6 n=6 Stimulation Index 100 n=6 n=6 10 * Minimum cut-off (2x) 1 1 dose 2 doses 3 doses 1 dose 2 doses 3 doses 0.1 mL DPX-Survivac 0.5 mL DPX-Survivac 50 mg Cyclophosphamide BID 50
Slide 16: DPX-0907 Phase I Trial Successfully Completed
DPX-0907 PHASE I TRIAL SUCCESSFULLY COMPLETED Well Tolerated and Immunogenic • US multi-center, open-label study – Enrolled 23 patients with Stage III/IV breast, ovarian or hormone-refractory prostate cancers – Endpoints: safety and immune activity • Safety Profile - was well tolerated – No serious
Slide 17: Infectious Disease
INFECTIOUS DISEASE ITV Immunovaccine
Slide 18: Developing Next-Generation Infectious Disease & Bio-Defense Vaccines
DEVELOPING NEXT-GENERATION INFECTIOUS DISEASE & BIO-DEFENSE VACCINES Partnerships Fueling our Future Pipeline • Malaria – Initial results show candidate’s potential to produce strong and sustained antibody responses, while reducing liver parasite load in a preclinical model • Respiratory Syncytial V
Slide 19: DepoVax Provides Protection Against Malaria
DEPOVAX PROVIDES PROTECTION AGAINST MALARIA Durable Immunity and Effective Protection with a Single Dose Antibody Titers By ELISA Parasite Liver Load Post-challenge (N=8) 312983 Average Log Titer (N=10) Number of Parasites 96% Reduction in Parasite Load 13330 1 Dose Non-Vaccinated Days Post-vaccinat
Slide 20: DepoVax-Based Anthrax Vaccine NIAID Primate Study
DEPOVAX-BASED ANTHRAX VACCINE NIAID PRIMATE STUDY 6 of 10 Animals Produced Sustained TNA Titers - A single dose of DPX-rPA vaccine produced sustained TNA (toxin-neutralizing antibody) titers detected in 6 of 10 animals starting between day 21 and 49. - Animals receiving one dose of Biothrax had no d
Slide 21: Cocaine Vaccine
COCAINE VACCINE Potentially First-of-its-Kind Vaccine Development Program • Collaboration with researchers at Weill Cornell Medical College • DepoVax adjuvanting technology combined with a novel cocaine antigen – Successfully blocked the delivery of cocaine to the brain in rodent challenge study – P
Slide 22: Animal Health
ANIMAL HEALTH ITV Immunovaccine
Slide 23: Partnering Animal Opportunities to Fuel Human Health Business
PARTNERING ANIMAL OPPORTUNITIES TO FUEL HUMAN HEALTH BUSINESS • Pfizer Animal Health - four licensing agreements signed – Cattle vaccines and other livestock applications – Pfizer funds research & development and commercialization activities – Immunovaccine receives: • Upfront signing fees, mileston
Slide 24: IMV Strategy Drives Value Creation
IMV STRATEGY DRIVES VALUE CREATION
Slide 25: IMV Strategy Drives Value Creation
IMV STRATEGY DRIVES VALUE CREATION • Leverage DepoVax™ as a potent, flexible and productive product platform • Advance both therapeutic cancer vaccine candidates into Phase II clinic trials • Take infectious disease programs into Phase I clinical trials • Capture upside through collaborative and par
Slide 26: Advance Clinical Development, Value Creation
ADVANCE CLINICAL DEVELOPMENT VALUE CREATION • DPX-Survivac and $500M 0907 Phase II data DPX-Malaria and RSV Phase II data Launch animal health vaccine with Strategic and Pfizer regional partners in place Non-dilutive financing supports DPX-Survivac DPX-Survivac Value Phase I data Phase II
Slide 27: Strong Leadership and Experience: Management & Board
STRONG LEADERSHIP AND EXPERIENCE MANAGEMENT & BOARD Management • John Trizzino, MBA 25 years experience, formerly Novavax, MedImmune Chief Executive Officer and Director (AstraZeneca) and ID BioMedical (GSK) • Marc Mansour, Ph.D. 12 years experience, expert in immunology Chief Science Officer • Vick
Slide 28: Immunovaccine Inc. (TSX-V: IMV)
IMMUNOVACCINE INC. (TSX-V: IMV) For more information: T: 902-492-1819 E: info@imvaccine.com www.imvaccine.com